Login to Your Account

Lilly pays Keybioscience $55M up front for novel drugs targeting diabetes

By Cormac Sheridan
Staff Writer

Thursday, June 8, 2017

DUBLIN – Eli Lilly and Co. is paying Keybioscience AG $55 million up front and is also on the hook for potential milestone payments arising from an alliance focused on a new drug class, dubbed Dacras.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription